Physician

Matthew R Skelton, MD

According to 2025 Medicare claims, Matthew Skelton, MD (NPI: 1689614919) practices medical oncology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (NPI: 1487621496; TIN: 541922084) and primary practice location at 24014-2419. Skelton is affiliated with the Doctors Connected (ACO ID: A4949), participating under the MSSP model.

Skelton's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 695 traditional Medicare patients, billed 159,984 HCPCS/CPT codes, and received $3,005,493 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,327 prescription claims across 231 beneficiaries totaling $3,855,030 in drug costs, led by Tasigna (Nilotinib Hcl). DME data shows 79 claims. Open Payments data shows 8 records totaling $177. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,489,981 to $3,855,030. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,309 to $868.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	759	148,651	$2,001,595
2016	806	182,335	$2,830,242
2017	814	177,819	$2,878,085
2018	804	177,180	$2,660,733
2019	809	198,187	$3,094,541
2020	802	200,085	$3,183,260
2021	766	184,721	$3,201,050
2022	805	171,776	$3,091,548
2023	731	151,482	$2,640,476
2024	695	159,984	$3,005,493

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	211	1,432	$1,489,981
2016	241	1,605	$1,577,674
2017	264	1,798	$2,213,276
2018	243	1,654	$2,529,306
2019	258	1,626	$2,774,380
2020	264	1,629	$3,402,076
2021	235	1,292	$3,437,474
2022	261	1,477	$4,285,127
2023	260	1,400	$4,174,714
2024	231	1,327	$3,855,030

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	159	$60,238
2016	100	248	$86,847
2017	184	590	$163,979
2018	156	598	$88,703
2019	71	243	$24,257
2020	65	370	$24,240
2021	42	151	$10,156
2022	57	176	$7,188
2023	42	117	$23,249
2024	13	79	$2,024

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	143	217	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	262	447	$59
80053	Blood test, comprehensive group of blood chemicals	341	1,355	$10
36415	Insertion of needle into vein for collection of blood sample	325	884	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	360	1,605	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tasigna	Nilotinib Hcl	14	392	$267,761
Vonjo	Pacritinib Citrate	11	330	$267,614
Brukinsa	Zanubrutinib	17	510	$258,905
Nubeqa	Darolutamide	18	540	$251,125
Erleada	Apalutamide	16	480	$244,135

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	26	$880
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$492
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	13	25	$452
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$177	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew R. Skelton, MD?

Tedicare shows public-source Medicare data for Matthew R. Skelton, MD (NPI 1689614919), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew R. Skelton, MD have ACO affiliation data?

Matthew R. Skelton, MD is shown with ACO affiliation data for Doctors Connected (MSSP, ACO ID A4949).

What billing organization is linked to Matthew R. Skelton, MD?

Matthew R. Skelton, MD is linked to ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (billing NPI 1487621496) in the available physician profile data.

Does Matthew R. Skelton, MD have Open Payments data?

Matthew R. Skelton, MD has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.